Partner Content Partner Content Ensuring a more informed and effective oncology drug develop... The rush to discover the next big frontier in cancer medicine is more evident than it ever has been since the introduction of targeted therapies.
Partner Content Partner Content VIDEO: Streamlining the process of patient enrollment Ever more-specific cancer medicines carry the advantage of more personalised treatments for those with the disease.
News New breakthrough designations for Roche's Alecensa and Actem... Alecensa and Roactemra are breakthroughs, says FDA.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News AZ's Tagrisso first to be funded through new Cancer Drugs Fu... New-look CDF pays for lung drug Tagrisso
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
